Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Open access
Dimopoulos, Meletios A., García-Sanz, Ramón, Gavriatopoulou, Maria, Morel, Pierre, Kyrtsonis, Marie-Christine, Michalis, Eurydiki, Kartasis, Zafiris, Leleu, Xavier, Palladini, Giovanni, Tedeschi, Alessandra, Gika, Dimitra, Merlini, Giampaolo, Kastritis, Efstathios, Sonneveld, Pieter·2013·Blood

Abstract

Key Points: BDR is an active regimen and induces long-lasting responses in patients with newly diagnosed WM. Induction with single-agent bortezomib may be effective in preventing complications of hyperviscosity or rituximab-induced IgM flare.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-05-503862

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 208

Metadata

Authors
Dimopoulos, M. A., García-Sanz, R., Gavriatopoulou, M., Morel, P., Kyrtsonis, M.-C., Michalis, E., Kartasis, Z., Leleu, X., Palladini, G., Tedeschi, A., Gika, D., Merlini, G., Kastritis, E., & Sonneveld, P.
Venue
Blood
Published
2013-11-07
Volume
122
Issue
19
Pages
3276-3282
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2091319225
Cited by
208
References
2
FWCI
9.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). https://app.cochat.ai/papers/10.1182/blood-2013-05-503862
The paper
Dimopoulos, M. A., García-Sanz, R., Gavriatopoulou, M., Morel, P., Kyrtsonis, M.-C., Michalis, E., Kartasis, Z., Leleu, X., Palladini, G., Tedeschi, A., Gika, D., Merlini, G., Kastritis, E., & Sonneveld, P. (2013). Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. https://doi.org/10.1182/blood-2013-05-503862

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.